Safety and risks in stem cell treatment: what to ask before consenting

Collection risk depends on the source: adipose harvesting is a minor procedure with risks of bleeding, bruising and wound infection, while bone marrow collection is more uncomfortable.

Culture risk concerns contamination and quality control, so ask to what standard the laboratory operates, whether sterility testing is done before use and whether the results are available to view.

Administration risk depends on route: intravenous delivery can produce infusion reactions such as chills, low-grade fever or blood pressure changes, so medical monitoring is required.

An overlooked systemic risk is weak screening — no cancer history taken, no medication review, no assessment for current infection. A good provider has these steps clearly in place.

Always ask who performs the procedure and with what credentials, what the cell source is, how follow-up works, and whom to contact if an adverse event occurs after returning home.

Designation as an advanced regenerative medicine institution by Korea's Ministry of Health and Welfare in March 2025 is verifiable regulatory information and should be weighed alongside the answers above.